400-94-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Nitro-4-fluorobenzoyl chloride is used as a reactant in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Nitro-4-fluorobenzoyl chloride is used as a reactant for the production of various agrochemicals. Its reactivity and chemical properties make it suitable for the synthesis of compounds with pesticidal or herbicidal activities, contributing to the development of effective crop protection agents.
Used in Dye Industry:
3-Nitro-4-fluorobenzoyl chloride is also utilized in the dye industry as a reactant for the synthesis of dyes with specific color properties. Its chemical structure enables the creation of dyes with unique characteristics, such as improved colorfastness or brightness, which can be applied in various industries, including textiles and printing.

InChI:InChI=1/C7H3ClFNO3/c8-7(11)4-1-2-5(9)6(3-4)10(12)13/h1-3H

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 79-37-8 oxalyl dichloride 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 402-42-6 4-fluoro-1-trichloromethylbenzene 
• 831-55-0 4-Fluor-5-nitrophenylchloroform 

Downstream Products

• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 453-99-6 4-fluoro-3-nitro-benzoic acid propyl ester 
• 328-17-6 4-fluoro-3-nitro-benzoic acid-(2-dimethylamino-ethyl ester); hydrochloride 
• 367-80-6 ethyl 4-fluoro-3-nitrobenzoate 
• 329-60-2 4-fluoro-3-nitro-benzoic acid-(3-diethylamino-propylester); hydrochloride 
• 403-02-1 4-fluoro-3-nitro-benzoic acid-(2-dipropylamino-ethyl ester); hydrochloride 
• 497-91-6 4-fluoro-3-nitro-benzoic acid-(3-dipropylamino-propylester); hydrochloride 
• 41263-65-4 4-amino-3-nitrobenzamide 
• 349-02-0 4-fluoro-3-nitrobenzamide 
• 342-15-4 O³,O⁵-((Ξ)-benzylidene)-O⁶-(4-fluoro-3-nitro-benzoyl)-O¹,O²-isopropylidene-α-D-glucofuranose 
• 3871-42-9 4-fluoro-3-nitro-benzoic acid-(2-diethylamino-ethyl ester); hydrochloride 
• 215050-13-8 2-benzenesulfonylamino-3-(4-fluoro-3-nitro-benzoylamino)-propionic acid tert-butyl ester 
• 215050-14-9 3-(4-fluoro-3-nitro-benzoylamino)-2-(naphthalene-2-sulfonylamino)-propionic acid tert-butyl ester 

Relevant academic research and scientific papers

Solid-phase synthesis of benzimidazole libraries biased for RNA targets

An efficient and highly versatile synthesis of two libraries 1(x,y) and 2-Ar(x,y,z) or 2-R2(x,y,w) based on the privileged benzimidazole scaffold is described. Our design is aimed at obtaining molecules, biased for binding to RNA targets, by in

Structure-Based Design of Dual Partial Peroxisome Proliferator-Activated Receptor γagonists/Soluble Epoxide Hydrolase Inhibitors

Polypharmaceutical regimens often impair treatment of patients with metabolic syndrome (MetS), a complex disease cluster, including obesity, hypertension, heart disease, and type II diabetes. Simultaneous targeting of soluble epoxide hydrolase (sEH) and p

COMPOUNDS WITH ANTIMICROBIAL ACTIVITY

Provided herein are compounds useful in the treatment of bacterial infections, pharmaceuticals comprising the same, and methods of use and preparation thereof.

Preparation method of 3-acetylindole BRPF1 inhibitor and use of 3-acetylindole BRPF1 inhibitor

The invention relates to a 3-acetylindole compound of a novel structure shown in a formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate or a solvate thereof, a preparation method of the compound, a pharmaceutical composition containing a therapeutically effective dose of the compound, and use thereof as a protein tyrosine kinase inhibitor, especially as a bromine-containing area PHD zinc finger protein 1 (BRPF1) inhibitor, in the prevention or treatment of disease benefited from the inhibition of BRPF1.

ACLY INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

Synthesis, docking, 3-D-qsar, and biological assays of novel indole derivatives targeting serotonin transporter, dopamine D2 receptor, and mao-a enzyme: In the pursuit for potential multitarget directed ligands

A series of 27 compounds of general structure 2,3-dihydro-benzo[1,4]oxazin-4-yl)-2-{4-[3-(1H-3indolyl)-propyl]-1-piperazinyl}-ethanamides, Series I: 7(a-o) and (2-{4-[3-(1H-3-indolyl) -propyl]-1-piperazinyl}-acetylamine)-N-(2-morfolin-4-yl-ethyl)-fluorinated benzamides Series II: 13(a-l) were synthesized and evaluated as novel multitarget ligands towards dopamine D2 receptor, serotonin transporter (SERT), and monoamine oxidase-A (MAO-A) directed to the management of major depressive disorder (MDD). All the assayed compounds showed affinity for SERT in the nanomolar range, with five of them displaying Ki values from 5 to 10 nM. Compounds 7k, Ki = 5.63 ± 0.82 nM, and 13c, Ki = 6.85 ± 0.19 nM, showed the highest potencies. The affinities for D2 ranged from micro to nanomolar, while MAO-A inhibition was more discrete. Nevertheless, compounds 7m and 7n showed affinities for the D2 receptor in the nanomolar range (7n: Ki = 307 ± 6 nM and 7m: Ki = 593 ± 62 nM). Compound 7n was the only derivative displaying comparable affinities for SERT and D2 receptor (D2/SERT ratio = 3.6) and could be considered as a multitarget lead for further optimization. In addition, docking studies aimed to rationalize the molecular interactions and binding modes of the designed compounds in the most relevant protein targets were carried out. Furthermore, in order to obtain information on the structure-activity relationship of the synthesized series, a 3-D-QSAR CoMFA and CoMSIA study was conducted and validated internally and externally (q2 = 0.625, 0.523 for CoMFA and CoMSIA and r2ncv = 0.967, 0.959 for CoMFA and CoMSIA, respectively).

Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors

Formation of a bacterial RNA polymerase (RNAP) holoenzyme by a catalytic core RNAP and a sigma (σ) initiation factor is essential for bacterial viability. As the primary binding site for the housekeeping σ factors, the RNAP clamp helix domain represents an attractive target for novel antimicrobial agent discovery. Previously, we designed a pharmacophore model based on the essential amino acids of the clamp helix, such as R278, R281, and I291 (Escherichia coli numbering), and identified hit compounds with antimicrobial activity that interfered with the core-σ interactions. In this work, we rationally designed and synthesized a class of triaryl derivatives of one hit compound and succeeded in drastically improving the antimicrobial activity against Streptococcus pneumoniae, with the minimum inhibitory concentration reduced from 256 to 1 μg/mL. Additional characterization of antimicrobial activity, inhibition of transcription, in vitro pharmacological properties, and cytotoxicity of the optimized compounds demonstrated their potential for further development.

Substituent effects on the isomerization of hydrazone switches driven by the intramolecular hydrogen bond

In this work, the substituent effects on hydrogen bonding in one kind of hydrazone-based switch are revealed. The E/Z isomerization ratios of these hydrazones and their intramolecular hydrogen bond strengths in the Z form were evaluated using NMR technique. Linear correlations between these parameters and Hammett empirical values for substituent effects are explored as well.

Thiazole-containing propyne amide derivative as well as preparation method and pharmaceutical composition and application thereof

The invention relates to propynamide derivatives shown in a formula I as well as pharmaceutically acceptable salt and preparation method thereof, a composition containing one or more of the compounds, and an application of the compounds to treatment of tu

NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT

The invention is directed to new class of quinolone heterocyclic aromatic molecules (Renotinibs) and their use in the treatment of cancer, in particular, cancer that harbor abnormal human epidermal growth factor receptors (EGFRs).